Episodic Migraine
Conditions
Keywords
prevention, prophylactic
Brief summary
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
Interventions
DRUGGalcanezumab
Administered SC
DRUGPlacebo
Administered SC
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Participants must have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 (1.1 or 1.2) (ICHD-3 2018) with a history of migraine of at least 1 year prior to screening and migraine onset prior to age 50 * Prior to screening, participants must have a history of 4-14 migraine headache days and at least 2 migraine attacks per month on average within the past 3 months
Exclusion criteria
* Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study * Current use or prior exposure to galcanezumab or another calcitonin gene-related peptide (CGRP) antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody * Participants who are taking, or are expected to take, therapeutic antibodies during the course of the study (for example, adalimumab, infliximab, trastuzumab, bevacizumab, etc.) * Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab * Women who are pregnant or nursing * History of chronic migraine, daily persistent headache, cluster headache, medication overuse headache, migraine with brainstem aura, or hemiplegic migraine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | Baseline, 3 Months | MHD is a calendar day on which a migraine or probable migraine (a headache missing 1 of the migraine features) occurred. Per International Headache Society \[IHS\] International Classification of Headache Disorders 3rd edition \[ICHD-3\], migraine is defined as a headache, with or without aura, of ≥30 minutes duration with the following required features (A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity (B) During headache at least 1 of the following: Nausea and/or vomiting; Photophobia and phonophobia. Overall mean is derived from the average of months 1 to 3 with Least square (LS) mean change calculated using mixed model repeat measures (MMRM) model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality-of-Life Questionnaire Version 2.1 (MSQ v2.1) During the Double-blind Treatment Phase. | Baseline, 3 Months | MSQ v2.1 is a self-administered instrument that was developed to address physical, emotional limitations of specific concern to individuals with migraine. It consists of 14 items that address 3 domains: Role Function-Restrictive (items 1-7), Role Function- Preventive (items 8-11) and Emotional Function (items 12-14). All item responses ranges from 1 (none of the time) to 6 (all of the time). Total raw scores for each domain is the sum of the raw scores of each item in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status & a positive change in scores reflecting functional improvement. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Headache During the Double-blind Treatment Phase. | Baseline, 3 Months | Number of monthly migraine headache days requiring medication for the acute treatment of headache is defined as the number of calendar days in a 30-day period on which migraine or probable migraine occurs and acute medication is used. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Overall Mean Change From Baseline in the Number of Monthly Headache Days During the Double-blind Treatment Phase. | Baseline, 3 Months | Number of monthly headache days is the number of calendar days in a 30-day period on which a headache occurs. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Percentage of Participants Who Maintain 50% Response Criteria During the Double-blind Treatment Phase. | Month 1 to Month 3 | Percentage of participants who maintained 50% response rate to treatment in all 3 months of the double-blind treatment phase. |
| Overall Mean Change From Baseline in Number of Monthly Migraine Attacks During the Double-blind Treatment Phase. | Baseline, 3 Months | Number of monthly migraine attacks is the number of sets of consecutive days with migraine or probable migraine separated by at least one migraine-free day in a 30-day period day. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Overall Mean Change From Baseline in Number of Monthly Migraine Headache Hours During the Double-blind Treatment Phase. | Baseline, 3 Months | Number of monthly migraine headache hours is the total number of headache hours in a 30-day period on days when a migraine or probable migraine occurs. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 3 Months | Participant having: * 30% or greater reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 30% response rate to treatment or 30% responder. * 50% or greater reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 50% response rate to treatment or 50% responder. * 75% or greater reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 75% response rate to treatment or 75% responder. * 100% reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 100% response rate to treatment or 100% responder. Overall mean is derived from the average of months 1 to 3 using generalized linear mixed model (GLIMMIX) with the fixed categorical effects of treatment, month, and treatment-by-month interaction, as well as the continuous, fixed covariate of baseline value. |
| Overall Mean Change From Baseline in Severity of Migraine Headaches During the Double-blind Treatment Phase. | Baseline, 3 Months | Severity of Migraine Headache was measured on a headache severity scale ranging from 1 to 3 with 1=mild, 2=moderate, and 3=severe. The mean severity of migraine headache for each month will be calculated as: sum of severity of migraine headache days divided by number of migraine headache days. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score at Month 3 During the Double-blind Treatment Phase. | Baseline, Month 3 | PGI-S is a 7-point scale that measures participants own global impression of their illness severity. The participant was instructed as follows: Considering migraine as a chronic condition, how would you rate your level of illness? Response options range from 1 (normal, not at all ill) to 7 (extremely ill). LS mean change was calculated using analysis of variance (ANCOVA) model with fixed categorical effects of treatment, country, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score at Month 3 During the Double-blind Treatment Phase. | Baseline, Month 3 | The MIDAS was designed to quantify headache-related disability over a 3-month period. This instrument consists of 5 items that measures the impact that migraine headaches have on migraineurs' life, including days of work/school missed, days with productivity at work/school reduced to half or more, days with household work missed, days with productivity in household work reduced to half or more, and days missed family/social/leisure activities. Each item has a numeric response range from 0 to 90 days; if days are missed from work/school or household work they are not counted as days with reduced productivity at work/school or household work. The numeric responses are summed to produce a total score ranging from 0 to 270. A higher value is indicative of more disability. LS mean change was calculated using ANCOVA model with fixed categorical effects of treatment, country, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
| Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA) During the Double-blind Treatment Phase. | Baseline to Month 3 | A TE-ADA evaluable participant is considered to be TE-ADA positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA positive if there is at least one post baseline result of ADA Present with titer \>= 20. |
| Pharmacokinetics (PK): Serum Concentration of Galcanezumab During the Double-blind Treatment Phase. | Month 3 | PK: Serum concentration of galcanezumab |
| Overall Mean Change From Baseline in Number of Monthly Headache Hours During the Double-blind Treatment Phase. | Baseline, 3 Months | Number of monthly headache hours is the total number of headache hours in a 30-day period on which a headache occurred. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction. |
Countries
China, India, Russia
Participant flow
Recruitment details
The study was designed to be conducted in three phases: a 3-month double-blind treatment phase, an optional 3-month open-label treatment phase and a 4-month follow-up phase.
Participants by arm
| Arm | Count |
|---|---|
| Placebo * Double-blind treatment phase: Participants received placebo once per month SC for 3 months during this phase.
* Open-label treatment phase: After completion of double-blind phase, participants could enter open-label treatment phase where they received 240 mg loading dose of galcanezumab SC (2 injections of 120 mg) in the first month followed by 120 mg per month for 2 months.
* Follow-up phase: After completion or discontinuation from double-blind or open-label treatment phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered. | 259 |
| Galcanezumab 120 mg * Double-blind treatment phase: Participants received 240 mg loading dose of galcanezumab SC (2 injections of 120 mg) in the first month followed by 120 mg per month for 2 months.
* Open-label treatment phase: After completion of double-blind phase, participants could enter open-label treatment phase where they continued to receive 120 mg galcanezumab SC per month for 3 months.
* Follow-up phase: After completion or discontinuation from double-blind or open-label treatment phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered. | 261 |
| Total | 520 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Double-Blind Treatment Phase | Adverse Event | 0 | 6 |
| Double-Blind Treatment Phase | Physician Decision | 1 | 3 |
| Double-Blind Treatment Phase | Pregnancy | 2 | 1 |
| Double-Blind Treatment Phase | Protocol Violation | 1 | 1 |
| Double-Blind Treatment Phase | Withdrawal by Subject | 13 | 5 |
| Follow-up Phase | Adverse Event | 0 | 1 |
| Follow-up Phase | Lost to Follow-up | 0 | 1 |
| Follow-up Phase | Protocol Violation | 0 | 2 |
| Follow-up Phase | Withdrawal by Subject | 7 | 5 |
| Open-Label Treatment Phase | Adverse Event | 1 | 2 |
| Open-Label Treatment Phase | Pregnancy | 1 | 0 |
| Open-Label Treatment Phase | Protocol Violation | 0 | 2 |
| Open-Label Treatment Phase | Withdrawal by Subject | 5 | 7 |
Baseline characteristics
| Characteristic | Galcanezumab 120 mg | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 37.20 years STANDARD_DEVIATION 9.33 | 37.00 years STANDARD_DEVIATION 9.57 | 36.80 years STANDARD_DEVIATION 9.83 |
| Monthly Migraine Headache Days (MHD) | 8.16 days per month STANDARD_DEVIATION 2.83 | 8.25 days per month STANDARD_DEVIATION 2.76 | 8.34 days per month STANDARD_DEVIATION 2.7 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 239 Participants | 478 Participants | 239 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 22 Participants | 42 Participants | 20 Participants |
| Region of Enrollment China | 198 Participants | 396 Participants | 198 Participants |
| Region of Enrollment India | 41 Participants | 82 Participants | 41 Participants |
| Region of Enrollment Russia | 22 Participants | 42 Participants | 20 Participants |
| Sex: Female, Male Female | 188 Participants | 384 Participants | 196 Participants |
| Sex: Female, Male Male | 73 Participants | 136 Participants | 63 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 259 | 0 / 261 | 0 / 241 | 0 / 243 | 0 / 7 | 0 / 11 | 0 / 236 | 0 / 236 |
| other Total, other adverse events | 29 / 259 | 32 / 261 | 12 / 241 | 7 / 243 | 0 / 7 | 0 / 11 | 0 / 236 | 0 / 236 |
| serious Total, serious adverse events | 3 / 259 | 2 / 261 | 9 / 241 | 3 / 243 | 0 / 7 | 0 / 11 | 3 / 236 | 4 / 236 |
Outcome results
Primary
Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase.
MHD is a calendar day on which a migraine or probable migraine (a headache missing 1 of the migraine features) occurred. Per International Headache Society \[IHS\] International Classification of Headache Disorders 3rd edition \[ICHD-3\], migraine is defined as a headache, with or without aura, of ≥30 minutes duration with the following required features (A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity (B) During headache at least 1 of the following: Nausea and/or vomiting; Photophobia and phonophobia. Overall mean is derived from the average of months 1 to 3 with Least square (LS) mean change calculated using mixed model repeat measures (MMRM) model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | -1.99 days per month | Standard Error 0.23 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | -3.81 days per month | Standard Error 0.23 |
p-value: <0.000195% CI: [-2.32, -1.32]Mixed Models Analysis
Secondary
Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score at Month 3 During the Double-blind Treatment Phase.
PGI-S is a 7-point scale that measures participants own global impression of their illness severity. The participant was instructed as follows: Considering migraine as a chronic condition, how would you rate your level of illness? Response options range from 1 (normal, not at all ill) to 7 (extremely ill). LS mean change was calculated using analysis of variance (ANCOVA) model with fixed categorical effects of treatment, country, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, Month 3
Population: All randomized participants who received at least one dose of study drug and had baseline value, non-missing post baseline value at month 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score at Month 3 During the Double-blind Treatment Phase. | -0.610 score on a scale | Standard Error 0.0961 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score at Month 3 During the Double-blind Treatment Phase. | -0.834 score on a scale | Standard Error 0.093 |
p-value: 0.028495% CI: [-0.43, -0.02]ANCOVA
Secondary
Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score at Month 3 During the Double-blind Treatment Phase.
The MIDAS was designed to quantify headache-related disability over a 3-month period. This instrument consists of 5 items that measures the impact that migraine headaches have on migraineurs' life, including days of work/school missed, days with productivity at work/school reduced to half or more, days with household work missed, days with productivity in household work reduced to half or more, and days missed family/social/leisure activities. Each item has a numeric response range from 0 to 90 days; if days are missed from work/school or household work they are not counted as days with reduced productivity at work/school or household work. The numeric responses are summed to produce a total score ranging from 0 to 270. A higher value is indicative of more disability. LS mean change was calculated using ANCOVA model with fixed categorical effects of treatment, country, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, Month 3
Population: All randomized participants who received at least one dose of study drug and had baseline value, non-missing post baseline value at month 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score at Month 3 During the Double-blind Treatment Phase. | -10.181 score on a scale | Standard Error 3.0597 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score at Month 3 During the Double-blind Treatment Phase. | -22.610 score on a scale | Standard Error 2.9582 |
p-value: 0.000195% CI: [-18.81, -6.05]ANCOVA
Secondary
Overall Mean Change From Baseline in Number of Monthly Headache Hours During the Double-blind Treatment Phase.
Number of monthly headache hours is the total number of headache hours in a 30-day period on which a headache occurred. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Number of Monthly Headache Hours During the Double-blind Treatment Phase. | -12.94 hours per month | Standard Error 2.06 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Number of Monthly Headache Hours During the Double-blind Treatment Phase. | -32.18 hours per month | Standard Error 2.03 |
p-value: <0.000195% CI: [-23.73, -14.75]Mixed Models Analysis
Secondary
Overall Mean Change From Baseline in Number of Monthly Migraine Attacks During the Double-blind Treatment Phase.
Number of monthly migraine attacks is the number of sets of consecutive days with migraine or probable migraine separated by at least one migraine-free day in a 30-day period day. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Number of Monthly Migraine Attacks During the Double-blind Treatment Phase. | -1.57 migraine attacks per month | Standard Error 0.12 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Number of Monthly Migraine Attacks During the Double-blind Treatment Phase. | -2.46 migraine attacks per month | Standard Error 0.12 |
p-value: <0.000195% CI: [-1.15, -0.62]Mixed Models Analysis
Secondary
Overall Mean Change From Baseline in Number of Monthly Migraine Headache Hours During the Double-blind Treatment Phase.
Number of monthly migraine headache hours is the total number of headache hours in a 30-day period on days when a migraine or probable migraine occurs. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Number of Monthly Migraine Headache Hours During the Double-blind Treatment Phase. | -12.83 hours per month | Standard Error 1.98 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Number of Monthly Migraine Headache Hours During the Double-blind Treatment Phase. | -31.72 hours per month | Standard Error 1.96 |
p-value: <0.000195% CI: [-23.21, -14.56]Mixed Models Analysis
Secondary
Overall Mean Change From Baseline in Severity of Migraine Headaches During the Double-blind Treatment Phase.
Severity of Migraine Headache was measured on a headache severity scale ranging from 1 to 3 with 1=mild, 2=moderate, and 3=severe. The mean severity of migraine headache for each month will be calculated as: sum of severity of migraine headache days divided by number of migraine headache days. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Severity of Migraine Headaches During the Double-blind Treatment Phase. | -0.03 score on a scale | Standard Error 0.03 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in Severity of Migraine Headaches During the Double-blind Treatment Phase. | -0.19 score on a scale | Standard Error 0.03 |
p-value: <0.000195% CI: [-0.22, -0.1]Mixed Models Analysis
Secondary
Overall Mean Change From Baseline in the Number of Monthly Headache Days During the Double-blind Treatment Phase.
Number of monthly headache days is the number of calendar days in a 30-day period on which a headache occurs. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Number of Monthly Headache Days During the Double-blind Treatment Phase. | -2.09 days per month | Standard Error 0.24 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Number of Monthly Headache Days During the Double-blind Treatment Phase. | -3.91 days per month | Standard Error 0.24 |
p-value: <0.000195% CI: [-2.35, -1.29]Mixed Models Analysis
Secondary
Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Headache During the Double-blind Treatment Phase.
Number of monthly migraine headache days requiring medication for the acute treatment of headache is defined as the number of calendar days in a 30-day period on which migraine or probable migraine occurs and acute medication is used. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Headache During the Double-blind Treatment Phase. | -0.71 days per month | Standard Error 0.22 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Headache During the Double-blind Treatment Phase. | -2.49 days per month | Standard Error 0.22 |
p-value: <0.000195% CI: [-2.25, -1.31]Mixed Models Analysis
Secondary
Overall Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality-of-Life Questionnaire Version 2.1 (MSQ v2.1) During the Double-blind Treatment Phase.
MSQ v2.1 is a self-administered instrument that was developed to address physical, emotional limitations of specific concern to individuals with migraine. It consists of 14 items that address 3 domains: Role Function-Restrictive (items 1-7), Role Function- Preventive (items 8-11) and Emotional Function (items 12-14). All item responses ranges from 1 (none of the time) to 6 (all of the time). Total raw scores for each domain is the sum of the raw scores of each item in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status & a positive change in scores reflecting functional improvement. Overall mean is derived from the average of months 1 to 3 with LS mean change calculated using MMRM model with fixed categorical effects of treatment, country, month, and treatment-by-month interaction, and the continuous fixed covariates of baseline value and baseline value-by-visit interaction.
Time frame: Baseline, 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality-of-Life Questionnaire Version 2.1 (MSQ v2.1) During the Double-blind Treatment Phase. | 13.94 score on a scale | Standard Error 0.88 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality-of-Life Questionnaire Version 2.1 (MSQ v2.1) During the Double-blind Treatment Phase. | 21.01 score on a scale | Standard Error 0.85 |
p-value: <0.000195% CI: [5.2, 8.95]Mixed Models Analysis
Secondary
Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase.
Participant having: * 30% or greater reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 30% response rate to treatment or 30% responder. * 50% or greater reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 50% response rate to treatment or 50% responder. * 75% or greater reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 75% response rate to treatment or 75% responder. * 100% reduction in the total number of MHDs relative to baseline in a 30-day period is considered to have 100% response rate to treatment or 100% responder. Overall mean is derived from the average of months 1 to 3 using generalized linear mixed model (GLIMMIX) with the fixed categorical effects of treatment, month, and treatment-by-month interaction, as well as the continuous, fixed covariate of baseline value.
Time frame: 3 Months
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 30% responder | 50.3 Percentage of participants | Standard Error 2.4 |
| Placebo - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 50% responder | 32.9 Percentage of participants | Standard Error 2.3 |
| Placebo - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 75% responder | 12.7 Percentage of participants | Standard Error 1.6 |
| Placebo - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 100% responder | 3.9 Percentage of participants | Standard Error 0.9 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 100% responder | 11.9 Percentage of participants | Standard Error 1.4 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 30% responder | 73.0 Percentage of participants | Standard Error 2.1 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 75% responder | 29.2 Percentage of participants | Standard Error 2.1 |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Overall Mean Percentage of Participants With ≥30%, ≥50%, ≥75%, 100% Reduction From Baseline in Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. | 50% responder | 54.9 Percentage of participants | Standard Error 2.4 |
Comparison: 30% responderp-value: <0.000195% CI: [2.01, 3.557]GLIMMIX
Comparison: 50% responderp-value: <0.000195% CI: [1.869, 3.293]GLIMMIX
Comparison: 75% responderp-value: <0.000195% CI: [2.007, 3.972]GLIMMIX
Comparison: 100% responderp-value: <0.000195% CI: [1.989, 5.504]GLIMMIX
Secondary
Percentage of Participants Who Maintain 50% Response Criteria During the Double-blind Treatment Phase.
Percentage of participants who maintained 50% response rate to treatment in all 3 months of the double-blind treatment phase.
Time frame: Month 1 to Month 3
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline value.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo - Double-Blind Treatment Phase | Percentage of Participants Who Maintain 50% Response Criteria During the Double-blind Treatment Phase. | 12.4 percentage of participants |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Percentage of Participants Who Maintain 50% Response Criteria During the Double-blind Treatment Phase. | 29.6 percentage of participants |
p-value: <0.000195% CI: [1.92, 4.81]Regression, Logistic
Secondary
Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA) During the Double-blind Treatment Phase.
A TE-ADA evaluable participant is considered to be TE-ADA positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA positive if there is at least one post baseline result of ADA Present with titer \>= 20.
Time frame: Baseline to Month 3
Population: All randomized participants who received at least one dose of study drug and had baseline, at least one non-missing post baseline ADA value.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo - Double-Blind Treatment Phase | Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA) During the Double-blind Treatment Phase. | 1.2 percentage of participants |
| Galcanezumab 120mg - Double-Blind Treatment Phase | Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA) During the Double-blind Treatment Phase. | 9.3 percentage of participants |
Secondary
Pharmacokinetics (PK): Serum Concentration of Galcanezumab During the Double-blind Treatment Phase.
PK: Serum concentration of galcanezumab
Time frame: Month 3
Population: All randomized participants who received at least one dose of galcanezumab and had evaluable serum concentrations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo - Double-Blind Treatment Phase | Pharmacokinetics (PK): Serum Concentration of Galcanezumab During the Double-blind Treatment Phase. | 14696 Nanogram per milliliter (ng/mL) | Standard Deviation 5675 |